Algernon Pharmaceuticals Completes Psychedelic Drug DMT Appoints UK Stroke Experts For Phase 2


VANCOUVER, British Columbia, 08 Dec. 2021 (GLOBE NEWSWIRE) – Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) clinical stage pharmaceutical development The Company is pleased to announce that it has completed the manufacture of its clinical grade supply (“cGMP”) of AP-188 (“NOT,NOT-Dimethyltryptamine or DMT ”) from the Canadian manufacturer Dalton Pharma Services. The Company believes that it has produced a sufficient supply of cGMP DMT to complete its Phase 1 and Phase 2 clinical trials.

The Company also announces that it has appointed Dr Anthony Rudd and Dr Robert Simister, both of the United Kingdom, as medical consultants for the Company’s DMT stroke clinical research program. Dr Rudd and Dr Simister both have extensive experience in stroke management as well as clinical care and stroke research. Their primary responsibility will be to help guide the Company’s Phase 2 clinical trials for the treatment of acute and post-stroke stroke, which are expected to start in the UK in late 2022, once the trial of phase 1 completed.

Dr Anthony Rudd

Anthony Rudd, MB, BChir, FRCP, CBE is Professor Emeritus of Stroke Medicine at Kings College London and recently retired as a Stroke Consultant at Guy’s and St Thomas Hospital. He was the London Stroke Clinical Director from 2010 to 2019 and the National Stroke Clinical Director for the NHS England from 2013 to 2019, where he oversaw dramatic improvements in the NHS stroke treatment paradigm .

For over 20 years, he chaired the Intercollegiate Stroke Working Group at the Royal College of Physicians, which was responsible for developing the National Stroke Clinical Guidelines and managing the National Sentinel Stroke Audit program. He chaired the National Institute for Health and Care Excellence (NICE) Guidelines Group for Acute Stroke and TIAs and the NICE Stroke Quality Standards Development Group. He is also past President of the British Association of Stroke Physicians and Honorary Vice President of the Stroke Association.

Dr Rudd was educated at Cambridge and King’s College London, where he obtained his medical degree in 1978. His research interests are stroke rehabilitation, organization of care and quality improvement . He has published over 300 peer-reviewed publications and supervised fourteen graduate degrees.

He was named CBE (Commander of the British Empire) in 2013 in recognition of his service to stroke medicine.

Dr Robert Simister

Robert Simister MA MB BS PhD FRCP is Consultant Neurologist and Stroke Physician, as well as Honorary Lecturer at University College London, where he is also Clinical Manager of the Comprehensive Stroke Service and Clinical Director of Medicine of the Stroke and acute neurology. Since 2019, he has been Clinical Co-Director of the London Stroke Clinical Network.

Dr Simister received his medical degree from Charing Cross and Westminster Medical School, now part of Imperial College London, and received his doctorate in neuroscience from University College London in 2012. In addition to his responsibilities as a consultant and director, he maintains a research program aimed at improving outcomes for stroke patients.

“Completing production of a cGMP supply of DMT is an important milestone for the company’s clinical stroke research program and this ensures that we will have a supply of the drug for our Phase 1 and 2 clinical trials. planned, “said Christopher J. Moreau, CEO of Algernon Pharmaceuticals Inc.” We are also very pleased that Dr Rudd and Dr Simister are joining us as medical consultants as we now begin the process of planning our studies of phase 2 for acute strokes and for post-stroke treatment. “

About Algernon Pharmaceuticals Inc.

Algernon is a drug re-conversion company that studies safe and already approved drugs, including natural compounds, for new disease applications, transferring them safely and efficiently into new human trials, developing new formulations and researching new regulatory approvals in global markets. Algernon specifically studies compounds that have never been approved in the United States or Europe to avoid off-label prescription writing.

CONTACT INFORMATION

Christophe J. Moreau
CEO
Algernon Pharmaceutical Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com

Neither the Canadian Securities Exchange nor its market regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

DISCLAIMER DISCLAIMER: No exchange has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this press release. This press release contains forward-looking statements relating to product development, licensing, marketing and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by words such as “will”, “may”, “should”, “anticipate”, “expect” and similar expressions. All statements other than statements of historical fact included in this press release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. Significant factors that could cause actual results to differ materially from the Company’s expectations include failure to comply with the conditions of the relevant stock exchange (s) and other risks detailed from time to time in documents filed by the Company. Company with securities regulations. The reader is cautioned that the assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those expected, due to many known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on forward-looking information. This information, although considered reasonable by management at the time of its preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release and the Company will publicly update or revise all included forward-looking statements as expressly required by applicable law.


Source link

Previous Lifestyle Communities launches latest campaign via By All Means
Next Global New Drug Reconstitution Systems Markets, 2021-2030